PCRX Dec 2024 47.500 call
| Previous Close | 1.0000 |
| Open | 1.0000 |
| Bid | 0.5500 |
| Ask | 1.2000 |
| Strike | 47.50 |
| Expire Date | 2024-12-20 |
| Day's Range | 1.0000 - 1.0000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 7 |
Simply Wall St.Earnings Miss: Pacira BioSciences, Inc. Missed EPS By 17% And Analysts Are Revising Their Forecasts
Investors in Pacira BioSciences, Inc. ( NASDAQ:PCRX ) had a good week, as its shares rose 9.3% to close at US$29.86...
GlobeNewswirePacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Pacira also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including,
- GlobeNewswire
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Pacira also intends to grant the initial purchasers of the notes an option to purchase, for
